Permutation-validated principal components analysis of microarray data

Table 1 Hybridizations performed in the CRH-R1 abolition experiment

Genotype (symbol)	Treatment (days)	Group ID	N
129Ola/CD1 knockout (k)	0	k0	4
129Ola/CD1 heterozygous (h)	0	h0	4
129Ola/CD1 heterozygous (h)	1	h1	5
129Ola/CD1 wild type (w)	0	w0	4
129Ola/CD1 wild type (w)	1	w1	4
129Ola/CD1 wild type (w)	7	w7	3
129SvJ wild type (s)	0	s0	4
129SvJ wild type (s)	1	s1	3
129SvJ wild type (s)	7	s7	2
Total			33

Thirty-three 12-week-old male mice with the genotypes shown in column 1 (k were CRH-R1 deficient animals, h and w were their littermates) were treated orally with an antagonist directed against the CRH-R1 (Janssen compound R121919) for 0, 1 or 7 days at a dose of 40 mg per kg body weight. Untreated groups (h0, w0, s0) were used to normalize the data and do not appear in Figures 5 and 6.

ISSN: 1474-760X